CLYM Stock — Climb Bio Inc

Climb Bio Inc (CLYM)

Updated October 16, 2026.

CLYM is a Stock. Total return is -38.2% over the past 5.2 years, 123.1 points behind SPY at 84.9%.

Climb Bio is a clinical-stage biotechnology company developing therapies for immune-mediated diseases, with its lead candidate budoprutug, an anti-CD19 monoclonal antibody in phase 2 trials for conditions including primary membranous nephropathy and immune thrombocytopenia, alongside a preclinical-stage APRIL monoclonal antibody program. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotech development with no expectation of current income, where returns would depend entirely on clinical trial success and future value appreciation.

CLYM performance versus SPY

Price and return data through 2026-10-16.

Total return is -38.2% over the past 5.2 years, 123.1 points behind SPY at 84.9%. Over the past year its total return — price change plus distributions reinvested — is 403.6%. Its deepest 1-year drawdown was 45.0%.

CLYM key facts

Asset type

Stock

Asset class

Equity

Inception date

08/10/2021

Distribution frequency

None

Last close

$9.82 (as of 2026-10-16)

Market cap

$564,024,024

Average volume

990343.0

Beta

-0.031

Payout ratio

0.0%

EPS

$-0.83

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CLYM risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 45.0%.

Who may consider CLYM — and who may not

It is a weaker fit for investors who need monthly cash flow (CLYM does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CLYM

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions